Golodirsen

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) are tanking Tuesday morning as a binary event turned up a negative outcome for the company. What Happened Sarepta announced Monday after the market close the FDA issued a complete response letter for its NDA seeking accelerated approval for...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared by more than 10 percent Wednesday after the company reported encouraging results from a clinical trial of a therapy intended to treat Duchenne muscular dystrophy (DMD). Sarepta's drug called golodirsen showed that patients who suffer from...